-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Our 12-month price target of $46 (lowered from $52) is 27.7x our 2027 EPS estimate, a small discount to the 28.4x forward average since the recent IPO. Our 2026 EPS estimate is $1.50 (up from $1.47), while our 2027 EPS estimate is $1.60 (down from $1.65). We look favorably on MDLN raising 2026 sales growth expectations despite looming headwinds facing the industry, supported by customer growth, including a new Prime Vendor signing with Mohwak Medbuy Corporation (serving nine acute care hospitals) in Canada. Looking ahead, MDLN sees reimbursement cuts and insurance coverage losses, stemming from recent policy developments such as the expiration of ACA enhanced premium tax credits and the passage of the One Big Beautiful Bill Act, which may cause moderation in healthcare utilization during 2H 2026. We also anticipate margin pressure from inflationary fuel, plastics, and other material costs. We maintain our Hold rating.